alkylating agent

Adverse effects

• increased incidence of acute myelocytic leukemia (AML)
  • often preceded by myelodysplastic syndrome
  • peak incidence 4-6 years after alkylating agent therapy
• non-random cytogenetic abnormalities
  • chromosome 7 deletions
  • trisomy 8

• drug adverse effects of alkylating agents

More general terms

• antineoplastic agent (chemotherapeutic agent)

More specific terms

• alkylating agent nitrogen mustard
• alkylating agent nitrosourea
• alkylating agent triazene
• altretamine (Hexalen)
• bendamustine (Treanda, Cytostasan, Ribomustin)
• busulfan (Myleran)
• diazomethane; azimethylene
• lurbinectedin (Zepzelca)
• phenoxybenzamine (Dibenzyline)
• procarbazine (Matulane, Natulan, ibenzmethyzin)
• thiotepa; thiophosphamide (Tespa, Thioplex)

Additional terms

• alkylating agent combination